Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Ardelyx Inc (ARDX) USD0.0001

Sell:$4.14 Buy:$4.70 Change: $0.11 (2.38%)
NASDAQ:0.83%
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$4.14
Buy:$4.70
Change: $0.11 (2.38%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
Sell:$4.14
Buy:$4.70
Change: $0.11 (2.38%)
Market closed |  Prices as at close on 18 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

Contact details

Address:
34175 Ardenwood Blvd
FREMONT
94555-3653
United States
Telephone:
+1 (510) 7457047
Website:
https://www.ardelyx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARDX
ISIN:
US0396971071
Market cap:
$272.56 million
Shares in issue:
62.80 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • David Mott
    Independent Chairman of the Board
  • Michael Raab
    President, Chief Executive Officer, Director
  • Mark Kaufmann
    Chief Financial Officer, Principal Accounting Officer
  • Elizabeth Grammer
    Senior Vice President, General Counsel
  • Jeremy Caldwell
    Chief Scientific Officer
  • David Rosenbaum
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.